FLT-PET Imaging for MDS

University of Wisconsin (UW)

Status: Terminated

Conditions: AML; MDS

Treatments: Procedure: FLT-PET scans

Study type: Interventional

Funder types: Other

Identifiers

NCT01535456

HO10417

2011-0285 (Other Identifier)

NCI-2012-00362 (Registry Identifier)

A534260 (Other Identifier)

SMPH\MEDICINE\HEM-ONC (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to see if this tracer can be used to determine how well chemotherapy is working in patients with certain types of leukemia.

Full description

Primary objectives

1. To evaluate if FLT-PET uptake shows variation during the treatment course in subjects with MDS being treated with 5-azacitidine therapy

   Secondary objectives

2. To assess FLT-PET uptake heterogeneity within given subjects being treated with 5-azacitidine therapy

3. To generate preliminary data regarding correlation between FLT-PET imaging parameters and clinical responses based on bone marrow aspirate/biopsy

Enrollment: 1 patient

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All subjects with previously untreated, Intermediate-2 or High risk myelodysplastic syndrome are eligible. These patients have an international prognostic scoring system (IPSS) score of 1.5 to 3.5 based on bone marrow blast percentage, karyotype, and the number of cytopenias 26.
• Subjects will receive the standard FDA-approved dose and schedule of 5-azacitidine. This dose is 75mg/m2 SQ or IV daily for seven days with cycles repeated every 28 days
• The subject's treating physician must have an initial intent of treating with at least four cycles of therapy
• Subjects must have an ECOG performance status of 0, 1, or 2
• Subjects must not have been treated with chemotherapy or radiation for another malignancy within the preceding 6 months
• Subjects must be > 18 years of age
• Subjects must have a serum creatinine < 2.0 mg/dL and/or calculated GHF 50 ml/min/1.73m (MRDR formula) or greater
• Subjects must have a serum direct bilirubin < 2.0 mg/dL unless related to Gilbert's syndrome of hemolysis. Alkaline phosphatase, SGOT (AST), and SGPT (ALT) must be less than 4 x upper limit of normal
• Women must not be pregnant nor breastfeeding
• Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception

Exclusion criteria

• Subjects who are pregnant or breast feeding

• Subjects for whom a therapy other than 5-azacitidine is recommended as first line treatment.

  • Allogeneic stem cell transplantation in patients with a suitable donor, lack of comorbidities, and good performance status

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

F-FLT PET scan, 5-azacitidine treatment

Experimental group

Description:

F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.

Treatment:

Procedure: FLT-PET scans